Draig Therapeutics has been backed by a number of global venture capital firms to help commercialise its pioneering therapies ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes ...

Q4 2025 Management View President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free ...

A breakthrough in breast cancer research is showing promising signs in the development of a vaccine for the disease. Anixa Biosciences, Inc. is working with the Cleveland Clinic to ...

While testing of colorectal cancer tumors for mismatch repair (MMR) defects has been recommended for years, the majority of ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.

Appointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) ...